Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease (GENPAD)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518122-33-00

Enrollment

2276

Registered

2024-12-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Brief summary

The primary outcome is the occurrence of adverse clinical events related to arterial thrombosis at 24 months, including death from any cause, major adverse cardiovascular events (MACE) and major adverse limb events (MALE).

Interventions

DRUGACETYLSALICYLIC ACID

DRUGCLOPIDOGREL

DRUGRIVAROXABAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary outcome is the occurrence of adverse clinical events related to arterial thrombosis at 24 months, including death from any cause, major adverse cardiovascular events (MACE) and major adverse limb events (MALE).	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026